Syndax Pharmaceuticals
Clinical trials sponsored by Syndax Pharmaceuticals, explained in plain language.
-
New hope for hard-to-treat leukemias: targeted combo enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called SNDX-5613 combined with strong chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific gene changes (KMT2A, NPM1, or NUP98). The main goals are to check safety and find the best dose. About 76 adult…
Phase: PHASE1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy shows promise in leukemia trial
Disease control Recruiting nowThis study tests whether adding the drug revumenib to standard chemotherapy helps people with a certain genetic type of acute myeloid leukemia (AML) live longer without the cancer coming back. About 468 adults with newly diagnosed AML and an NPM1 mutation will receive either revu…
Phase: PHASE3 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New hope for leukemia patients: targeted drug shows promise
Disease control Recruiting nowThis study tests a new drug called revumenib in people with certain types of leukemia that have come back or not responded to other treatments. The goal is to find the best dose and see if it can help control the disease. About 447 adults with specific genetic changes (MLL/KMT2A …
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:31 UTC